Local view for "http://purl.org/linkedpolitics/eu/plenary/2011-03-08-Speech-2-246-500"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20110308.22.2-246-500"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
"Fortunately, according to data provided by the European Centre for Disease Prevention and Control (ECDC), the H1N1 influenza virus caused fewer deaths than initially predicted, and is currently considered a disease of low severity in the EU. It created a certain amount of alarm at the beginning of its spread, which led several Member States to make substantial investments in vaccination programmes that turned out to be excessive, because in countries such as Poland, which did not take any exceptional measures, the mortality rate remained at the level of those countries that embarked on national vaccination campaigns, with costs estimated at many millions of euro.
According to this report, ‘the policies on the purchasing of vaccines had already been laid down in advance purchase agreements signed back in 2007 with pharmaceutical companies’. This reveals a lack of transparency in this procedure due to the Member States’ unacceptable dependence on pharmaceutical companies. Thus, I have to agree with the rapporteur, and hope that her recommendations, particularly with regard to certainty of information and the precautionary principle – which needs to benefit patients rather than companies – are taken into account by the Commission and by all Member States."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples